These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 38833177)

  • 41. Intratumoral follicular regulatory T cells curtail anti-PD-1 treatment efficacy.
    Eschweiler S; Clarke J; Ramírez-Suástegui C; Panwar B; Madrigal A; Chee SJ; Karydis I; Woo E; Alzetani A; Elsheikh S; Hanley CJ; Thomas GJ; Friedmann PS; Sanchez-Elsner T; Ay F; Ottensmeier CH; Vijayanand P
    Nat Immunol; 2021 Aug; 22(8):1052-1063. PubMed ID: 34168370
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Combination low-dose cyclophosphamide with check-point blockade and ionizing radiation promote an abscopal effect in mouse models of melanoma.
    Luo X; Zeng M
    J Cancer Res Ther; 2024 Apr; 20(2):718-725. PubMed ID: 38687945
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Immune Modulation by Telomerase-Specific Oncolytic Adenovirus Synergistically Enhances Antitumor Efficacy with Anti-PD1 Antibody.
    Kanaya N; Kuroda S; Kakiuchi Y; Kumon K; Tsumura T; Hashimoto M; Morihiro T; Kubota T; Aoyama K; Kikuchi S; Nishizaki M; Kagawa S; Tazawa H; Mizuguchi H; Urata Y; Fujiwara T
    Mol Ther; 2020 Mar; 28(3):794-804. PubMed ID: 31991110
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Microwave ablation combined with anti-PD-1/CTLA-4 therapy induces an antitumor immune response to renal cell carcinoma in a murine model.
    Guo RQ; Peng JZ; Li YM; Li XG
    Cell Cycle; 2023 Jan; 22(2):242-254. PubMed ID: 35980140
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer.
    Liu C; Liu R; Wang B; Lian J; Yao Y; Sun H; Zhang C; Fang L; Guan X; Shi J; Han S; Zhan F; Luo S; Yao Y; Zheng T; Zhang Y
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33462141
    [TBL] [Abstract][Full Text] [Related]  

  • 46. TOX-expressing terminally exhausted tumor-infiltrating CD8
    Han HS; Jeong S; Kim H; Kim HD; Kim AR; Kwon M; Park SH; Woo CG; Kim HK; Lee KH; Seo SP; Kang HW; Kim WT; Kim WJ; Yun SJ; Shin EC
    Cancer Lett; 2021 Feb; 499():137-147. PubMed ID: 33249194
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pan-TAM Tyrosine Kinase Inhibitor BMS-777607 Enhances Anti-PD-1 mAb Efficacy in a Murine Model of Triple-Negative Breast Cancer.
    Kasikara C; Davra V; Calianese D; Geng K; Spires TE; Quigley M; Wichroski M; Sriram G; Suarez-Lopez L; Yaffe MB; Kotenko SV; De Lorenzo MS; Birge RB
    Cancer Res; 2019 May; 79(10):2669-2683. PubMed ID: 30877108
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Monocyte-derived APCs are central to the response of PD1 checkpoint blockade and provide a therapeutic target for combination therapy.
    Schetters STT; Rodriguez E; Kruijssen LJW; Crommentuijn MHW; Boon L; Van den Bossche J; Den Haan JMM; Van Kooyk Y
    J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32690667
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Inhibition of vascular adhesion protein-1 enhances the anti-tumor effects of immune checkpoint inhibitors.
    Kinoshita T; Sayem MA; Yaguchi T; Kharma B; Morii K; Kato D; Ohta S; Mashima Y; Asamura H; Kawakami Y
    Cancer Sci; 2021 Apr; 112(4):1390-1401. PubMed ID: 33453147
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Radiofrequency radiation reshapes tumor immune microenvironment into antitumor phenotype in pulmonary metastatic melanoma by inducing active transformation of tumor-infiltrating CD8
    Jiao JZ; Zhang Y; Zhang WJ; He MD; Meng M; Liu T; Ma QL; Xu Y; Gao P; Chen CH; Zhang L; Pi HF; Deng P; Wu YZ; Zhou Z; Yu ZP; Deng YC; Lu YH
    Acta Pharmacol Sin; 2024 Jul; 45(7):1492-1505. PubMed ID: 38538718
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Abscopal Effects With Hypofractionated Schedules Extending Into the Effector Phase of the Tumor-Specific T-Cell Response.
    Zhang X; Niedermann G
    Int J Radiat Oncol Biol Phys; 2018 May; 101(1):63-73. PubMed ID: 29534901
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies.
    Kumagai S; Togashi Y; Kamada T; Sugiyama E; Nishinakamura H; Takeuchi Y; Vitaly K; Itahashi K; Maeda Y; Matsui S; Shibahara T; Yamashita Y; Irie T; Tsuge A; Fukuoka S; Kawazoe A; Udagawa H; Kirita K; Aokage K; Ishii G; Kuwata T; Nakama K; Kawazu M; Ueno T; Yamazaki N; Goto K; Tsuboi M; Mano H; Doi T; Shitara K; Nishikawa H
    Nat Immunol; 2020 Nov; 21(11):1346-1358. PubMed ID: 32868929
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Modulation of intratumoural myeloid cells, the hallmark of the anti-tumour efficacy induced by a triple combination: tumour-associated peptide, TLR-3 ligand and α-PD-1.
    Zalba S; Belsúe V; Topp B; de Alwis D; Alvarez M; Trocóniz IF; Berraondo P; Garrido MJ
    Br J Cancer; 2021 Mar; 124(7):1275-1285. PubMed ID: 33531689
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Distinct exhaustion features of T lymphocytes shape the tumor-immune microenvironment with therapeutic implication in patients with non-small-cell lung cancer.
    Kim CG; Kim G; Kim KH; Park S; Shin S; Yeo D; Shim HS; Yoon HI; Park SY; Ha SJ; Kim HR
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34907028
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets, biomarkers, and remedies.
    Pérez-Ruiz E; Melero I; Kopecka J; Sarmento-Ribeiro AB; García-Aranda M; De Las Rivas J
    Drug Resist Updat; 2020 Dec; 53():100718. PubMed ID: 32736034
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Priming is key to effective incorporation of image-guided thermal ablation into immunotherapy protocols.
    Silvestrini MT; Ingham ES; Mahakian LM; Kheirolomoom A; Liu Y; Fite BZ; Tam SM; Tucci ST; Watson KD; Wong AW; Monjazeb AM; Hubbard NE; Murphy WJ; Borowsky AD; Ferrara KW
    JCI Insight; 2017 Mar; 2(6):e90521. PubMed ID: 28352658
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Co-inhibitor expression on tumor infiltrating and splenic lymphocytes after dual checkpoint inhibition in a microsatellite stable model of colorectal cancer.
    Slovak RJ; Park HJ; Kamp WM; Ludwig JM; Kang I; Kim HS
    Sci Rep; 2021 Mar; 11(1):6956. PubMed ID: 33772035
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Intratumoral STING Activation with T-cell Checkpoint Modulation Generates Systemic Antitumor Immunity.
    Ager CR; Reilley MJ; Nicholas C; Bartkowiak T; Jaiswal AR; Curran MA
    Cancer Immunol Res; 2017 Aug; 5(8):676-684. PubMed ID: 28674082
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The synergistic immunotherapeutic impact of engineered CAR-T cells with PD-1 blockade in lymphomas and solid tumors: a systematic review.
    Satapathy BP; Sheoran P; Yadav R; Chettri D; Sonowal D; Dash CP; Dhaka P; Uttam V; Yadav R; Jain M; Jain A
    Front Immunol; 2024; 15():1389971. PubMed ID: 38799440
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Enhanced anti-tumor response elicited by a novel oncolytic HSV-1 engineered with an anti-PD-1 antibody.
    Tian C; Liu J; Zhou H; Li J; Sun C; Zhu W; Yin Y; Li X
    Cancer Lett; 2021 Oct; 518():49-58. PubMed ID: 34139284
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.